Polycystic ovary syndrome (PCOS)
Conditions
Interventions
Placebo group:Placebo, 4 tablets twice a day, 15 minutes before breakfast and dinner
At the same time, dietary and exercise instructions were given
Control group:Inositol, 4 tablets twice a day, 15 minutes before breakfast and dinner
Sponsors
The First Affiliated Hospital of Xiamen University
Eligibility
Sex/Gender
Female
Age
18 Years to 40 Years
Inclusion criteria
Inclusion criteria: 1. The age range is 18-40 years; 2. BMI<23.9kg/m^2; 3. The diagnosis was PCOS according to the Rotterdam diagnostic criteria of the PCOS International Collaboration Group. If 2 of the following 3 conditions are met, the diagnosis is PCOS (1) chronic ovulation disorder (2) clinical and/or hyperandrogenemia (3) ultrasound polycystic changes. 4.A ccording to the 75g OGTT test, insulin resistance/hyperinsulinemia was diagnosed, and any of the following conditions were met: 1) Fasting insulin was more than twice the normal reference value; 2) Peak insulin was more than 10 times the basic fasting value after glucose loading, and the area under the insulin curve increased; 3) After glucose stress, the peak of insulin secretion is delayed until 2h or 3h after taking sugar, and still cannot be reduced to fasting level; 5. Who signed the informed consent;
Exclusion criteria
Exclusion criteria: 1. There are other causes of ovarian dysfunction, such as hyperprolactinemia and hypothyroidism or hyperthyroidism; 2. Because of adrenal hyperplasia, Cushing's syndrome, androgen secreting tumors, or drugs caused by excessive androgen; 3. Drug-induced hypoovarian function or early-onset ovarian insufficiency (POI); 4. Patients with severe primary diseases of cardiovascular, cerebrovascular, liver, kidney and hematopoietic system, such as grade 4 heart function, acute stage of cerebral hemorrhage, serum aminotransferase greater than 2.5 times the upper limit of normal reference value, serum creatinine greater than 1.5mg/dL, etc. 5. Taking oral contraceptives (e.g., Datin, Yasmin, or Alacrine) or medications that may affect insulin sensitivity (e.g., metformin, pioglitazone) 1 month before enrollment; 6. Participants considered inappropriate for clinical trials;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Insulin sensitivity; | — |
Secondary
| Measure | Time frame |
|---|---|
| Ovulation status;Liver and kidney function;Blood lipids, uric acid;Weight, body fat percentage, muscle mass, lean body mass;Waist circumference and waist to hip ratio; | — |
Countries
China
Contacts
Public ContactZhiping Yang
The First Affiliated Hospital of Xiamen University
Outcome results
None listed